Health Care • Biotechnology: Pharmaceutical Preparations
$19.04 ▼ -0.16
(-0.86%)
MKT CAP: $22.05B • VOL: 8.79M
52W L $10 52W H $20
VTRS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $14.25B | $14.69B | $15.39B |
| YoY Revenue Growth % | -3.0% | -4.5% | — |
| Gross Profit | $5.01B | $5.62B | — |
| Gross Margin % | 35.2% | 38.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$2.66B | $10.1M | $766.2M |
| Operating Margin % | -18.7% | 0.1% | 5.0% |
| Net Income (GAAP) | $0 | $0 | $0 |
| EBITDA (Normalized) | -$2.36B | $270.9M | $1.32B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $2.32B | $2.30B | $2.90B |
| Capital Expenditures (CapEx) | $378.8M | $326.0M | $692.5M |
| Free Cash Flow (FCF) | $1.94B | $1.98B | $2.21B |
| FCF Margin % | 13.6% | 13.5% | 14.3% |
| Return on Invested Capital (ROIC %) | -8.1% | 0.0% | 5.4% |
| Cash & Short-Term Equivalents | $1.32B | $734.8M | — |
| Total Debt (Short + Long Term) | $12.48B | $14.04B | $4.32B |
| Total Stockholders' Equity | $14.71B | $18.64B | $8.86B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VTRS.